Abiraterone acetate/niraparib - Janssen
Alternative Names: AKEEGA; CJNJ-67652000Latest Information Update: 28 Oct 2023
At a glance
- Originator Janssen
- Class Androstenols; Antiandrogens; Antineoplastics; Benzamides; Indazoles; Phenanthrenes; Piperidines; Pyridines; Small molecules
- Mechanism of Action CYP17A1 protein inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 22 Oct 2023 Final efficacy and adverse events data from the phase III MAGNITUDE trial in Prostate cancer released by Janssen
- 20 Oct 2023 Updated efficacy data from the phase III MAGNITUDE trial in Prostate cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 20 Oct 2023 Updated efficacy and adverse events data from the phase III MAGNITUDE trial in Prostate cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)